14 results about "Midazolam" patented technology

The invention provides a sterile filling process control method and system for midazolam oral liquid nitrogen charging protection, and relates to the technical field of medicine filling process control. After midazolam oral liquid is subjected to nitrogen charging, a headspace gas multispectral image sequence in a bottle before sealing is collected through a transmission imaging system integrated with a filling line; extracting oxygen characteristic absorption wave band light intensity attenuation data through spectrum separation, and generating a bottleneck plane oxygen two-dimensional concentration diagram; calculating the local oxygen partial pressure of the pixel, and constructing a three-dimensional oxygen concentration field and marking an oxygen-enriched area by combining pre-stored geometric parameters of the bottle body; and then the model reference adaptive controller is used for comparing the model with an ideal nitrogen model to generate supplementary parameters containing purging angle, intensity and time, an execution mechanism is driven to perform fixed-point pulse purging, and after verification reaches the standard, a screw cap is used for sealing, so that accurate detection, directional processing and standard verification of the headspace oxygen-enriched area in the midazolam oral liquid bottle can be realized, and the safety of the midazolam oral liquid bottle is ensured. And the oxygen concentration before sealing meets the standard.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and / or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

This invention relates to a midazolam nanocrystal suspension, which, by weight-volume percentage, comprises 5%–45% midazolam, 1%–10% Tween, and 0.1%–10% sodium deoxycholate (SDC). The midazolam nanocrystal suspension of this invention exhibits superior blood-brain barrier permeability and bioavailability, making it suitable for needle-free injection administration.

The present invention relates to a unit dose composition comprising midazolam or a pharmaceutically acceptable salt thereof, cyclodextrin, and at least one matrix material, and to the use of the unit dose composition in pharmaceuticals and therapies, particularly in the treatment of febrile seizures, epileptic seizures, e.g., status epilepticus, fear, e.g., preoperative anxiety relief to alleviate fear, and / or agitation, e.g., preoperative agitation.

The invention provides an automatic optical detection method and system for visible foreign matters in a midazolam buccal mucosa solution, and relates to the technical field of drug detection.The automatic optical detection method comprises the steps that the midazolam buccal mucosa solution is controlled to flow in a transparent flow cell, and suspended particles in the solution are dynamically observed and recognized by means of an optical imaging system; controlling a polarized light source of the optical imaging system to rotate relative to the transparent flow cell, and collecting optical response data of each suspended particle at a plurality of rotation angles; then, according to the data, determining the change information of the light intensity along with the relative rotation angle, synchronously extracting color distribution information, and generating key feature data representing the optical response characteristics of the particles; and finally, comparing the key characteristic data with preset standard characteristic data of the raw material medicines and the auxiliary materials, so that the suspended particles are judged as raw material medicine crystals, auxiliary material precipitates or visible foreign matters, and automatic and accurate classification of the suspended particles in the midazolam buccal mucosa solution is realized.

The application provides a midazolam oral liquid nitrogen-filled protection sterile filling process control method and system, relates to the technical field of medicine filling process control, and the application collects a plurality of spectral images sequences of headspace gas in a bottle before sealing through a transmission imaging system integrated in a filling line after nitrogen filling of the midazolam oral liquid, extracts oxygen characteristic absorption waveband light intensity attenuation data through spectral separation, and generates a two-dimensional oxygen concentration graph of a bottle mouth plane; according to this, the pixel local oxygen partial pressure is calculated, the three-dimensional oxygen concentration field is constructed in combination with the pre-stored bottle body geometric parameters, and the oxygen-rich area is identified; then, the model reference self-adaptive controller is used to compare the oxygen-rich area with an ideal nitrogen model, generate complementary parameters containing a blowing angle, intensity and time, drive an actuating mechanism to perform point pulse blowing, and after verification that the standard is met, enter cap sealing, so that the oxygen-rich area in the headspace of the midazolam oral liquid bottle can be accurately detected, directionally treated and verified to meet the standard, and the oxygen concentration before sealing can meet the standard.

Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

The application provides a method and system for automatically optically detecting visible foreign matters in midazolam buccal mucosa solution, and relates to the technical field of drug detection. The application controls the flow of midazolam buccal mucosa solution in a transparent flow cell, dynamically observes and identifies suspended particles in the solution by means of an optical imaging system. Then, the polarized light source of the optical imaging system is controlled to rotate relative to the transparent flow cell, and optical response data of each suspended particle at multiple rotation angles is collected. Next, the change information of light intensity with the relative rotation angle is determined according to the data, and the color distribution information is synchronously extracted to generate key feature data representing the optical response characteristics of the particles. Finally, the key feature data is compared with the preset standard feature data of the raw materials and excipients, so that the suspended particles are determined as raw material crystals, excipient precipitates or visible foreign matters, and the automatic and accurate classification of the suspended particles in the midazolam buccal mucosa solution is realized.

The invention discloses a closed-loop transcranial stimulation system and a closed-loop transcranial stimulation method. 0.3 mg of scopolamine and 3 mg of midazolam are intramuscularly injected before an operation; after a patient enters a room, sufentanil is subjected to intravenous injection induced by right subclavian vein and radial artery puncture general anesthesia, propofol is subjected to target-control infusion, the plasma target concentration is 3.0 mu g / mL, vecuronium bromide is 0.15 mg / kg, tracheal intubation is performed after 5 min, general anesthesia maintains target-control infusion of propofol, and after the patient enters the room, the target-control infusion of propofol is performed. A TMS stimulation coil electricity-magnetism-heat-stress model, a single-phase and double-phase pulse discharge circuit model and a neuron dynamic response model under the action of a TMS are established, and the influence of TMS system parameters on space-time distribution characteristics of an intracranial induced electric field and neuron membrane potential can be accurately expressed. Behavior perception and system auditory stimulation are combined to be applied to nursing intervention of severe craniocerebral injury coma patients, self-repairing and consciousness awakening of the brain functions of the patients can be effectively promoted, and meanwhile recovery of limb functions and daily life ability of the patients is facilitated.

The application discloses a kind of pharmaceutical composition and its purposes in preparation for inhibiting the autonomous intake preference of ethanol. The pharmaceutical composition includes lorcaserin and midazolam. The pharmaceutical composition for inhibiting the autonomous intake preference of ethanol provided by the application can effectively reduce the desire of body to alcohol, is used to treat alcohol dependence, and has significant long-acting characteristics. When the pharmaceutical composition is administered to mice, the absolute amount of active ethanol intake of mice and the relative proportion of ethanol intake compared with the amount of drinking water can be significantly reduced, and the inhibitory effect can last at least 6 days, which is expected to update the treatment plan for alcohol addiction in clinic.

The present disclosure relates to a unit dose composition comprising midazolam or a pharmaceutically acceptable salt thereof, a cyclodextrin and at least one matrix material, and the use of the unit dose composition in medicine and therapy, the pharmaceutical composition is especially used for treating epileptic seizures such as febrile convulsion and persistent epilepsy, relieving anxiety before operation so as to relieve fear such as fear, and / or restlessness such as restlessness before operation.

This invention discloses a method for preparing midazolam impurity A and impurity B standards. It improves the preparation method of the key intermediate 4-hydroxymidazolam, using 4-hydroxymidazolam as a raw material and further preparing impurities A and B through different pathways. In the preparation of 4-hydroxymidazolam, only one post-processing step is performed, avoiding losses caused by multiple post-processing steps, improving yield, and resulting in high product purity. This, in turn, improves the purity of the target products, impurities A and B, providing strong support for the quality of midazolam pharmaceutical products.

Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.